ArcheNova plots Nasdaq debut via SPAC merger with Horizon Space
What's the deal? Horizon Space Acquisition I CorpDealroom has a profile for this one. Try Dealroom →, a publicly traded special purpose acquisition company, has signed a definitive agreement to merge with ArcheNova Biotech CorpDealroom has a profile for this one. Try Dealroom →, a clinical-stage biotech developing exosome-based therapies. The companies did not disclose a transaction value.
The mechanics: Upon completion, the combined business will operate through ArcheNova Technology Co, a newly formed Cayman Islands entity, with ordinary shares expected to trade on Nasdaq. The deal is slated to close in the first quarter of 2027, subject to regulatory and shareholder approvals.
What does ArcheNova do? It develops therapeutics derived from mesenchymal stromal cell extracellular vesicles and exosomes, aimed at tissue repair and regenerative medicine. The company is advancing five candidates across dermatology, orthopedics, ophthalmology, neurology, and cardiology.
Its lead program, a topical treatment for psoriasis, has completed a Phase I trial involving 10 healthy volunteers at Singapore's National University Hospital. ArcheNova is preparing it for Phase II.
Why it matters: ArcheNova builds its therapies on a proprietary platform using an immortalized monoclonal producer cell line, which it says addresses donor variability and batch-to-batch differences. It intends to apply common manufacturing processes and quality systems across its pipeline to support more efficient development.
Why now? A Nasdaq listing would hand ArcheNova access to a broader investor base. "Having access to the global capital market will empower our research and development as well as our novel pipeline products and fuel our growth and expansion," said Lim Sai Kiang, the company's chief executive officer and chief scientist.
For Horizon, the merger meets its stated goal. "ArcheNova's progress in developing exosome-based therapeutics for tissue repair and regenerative medicine aligns with our objective of partnering with an innovative company positioned to address significant unmet medical needs," said Mingyu "Michael" Li, Horizon's chief executive officer and chairman.
The signal: SPAC mergers remain a route for clinical-stage biotechs to reach public markets without a traditional IPO. With its therapies still early and subject to regulatory review, ArcheNova is betting that listed capital will carry its pipeline toward commercialisation.
Read more: citybiz.co
Image credit: Generated with Gemini
